The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Management of Hepatocellular Carcinoma: A Review
Abstract
Importance: Hepatocellular carcinoma (HCC) is the sixth most common malignancy and fourth leading cause of cancer-related death worldwide. Recent advances in systemic and locoregional therapies have led to changes in many guidelines regarding systemic therapy, as well as the possibility to downstage patients to undergo resection. This review examines the advances in surgical and medical therapies relative to multidisciplinary treatment strategies for HCC. Observations: HCC is a major health problem worldwide. The obesity epidemic has made nonalcoholic fatty liver disease a major risk factor for the development of HCC. Multiple societies, such as the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, the Asian Pacific Association for the Study of the Liver, and the National Comprehensive Cancer Network, provide guidelines for screening at-risk patients, as well as define staging systems to guide optimal treatment strategies. The Barcelona Clinic Liver Cancer staging system is widely accepted and has recently undergone updates with the introduction of new systemic therapies and stage migration. Conclusions and Relevance: The treatment of patients with HCC should involve a multidisciplinary approach with collaboration among surgeons, medical oncologists, radiation oncologists, and interventional radiologists to provide optimal care. Treatment paradigms must consider both tumor and patient-related factors such as extent of liver disease, which is a main driver of morbidity and mortality. The advent of more effective systemic and locoregional therapies has prolonged survival among patients with advanced disease and allowed some patients to undergo surgical intervention who would otherwise have disease considered unresectable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R. P., Trebicka, J., Krag, A., Laleman, W., & Gines, P. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.024 · Cited by 2,905
Cited by
Siegel, R. L., Kratzer, T. B., Wagle, N. S., Sung, H., & Jemal, A. (2026) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70043 · Cited by 403
Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 281
Spatial immune scoring system predicts hepatocellular carcinoma recurrence
Jia, G., He, P., Dai, T., Goh, D., Wang, J., Sun, M., Wee, F., Li, F., Lim, J. C. T., Hao, S., et al. (2025) · Nature · doi:10.1038/s41586-025-08668-x · Cited by 104
Sharma, N., Singh, L., Sharma, A., Kumar, A., & Mahajan, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107375 · Cited by 16
Metadata
- Authors
- Brown, Z. J., Tsilimigras, D. I., Ruff, S. M., Mohseni, A., Kamel, I. R., Cloyd, J. M., & Pawlik, T. M.
- Venue
- JAMA Surgery
- Publisher
- American Medical Association (AMA)
- Published
- 2023-04-01
- Volume
- 158
- Issue
- 4
- Pages
- 410
- ISSN
- 2168-6254 (ISSN-L)
- OpenAlex
- W4320856583
- Cited by
- 763
- References
- 80
- FWCI
- 108.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Hepatocellular Carcinoma: A Review. https://app.cochat.ai/papers/10.1001/jamasurg.2022.7989
- The paper
- Brown, Z. J., Tsilimigras, D. I., Ruff, S. M., Mohseni, A., Kamel, I. R., Cloyd, J. M., & Pawlik, T. M. (2023). Management of Hepatocellular Carcinoma: A Review. JAMA Surgery. https://doi.org/10.1001/jamasurg.2022.7989
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.